Vaccination Program — Cost, Top Hospitals & Success Rates | MyMedicPlus

A vaccination program is a systematic, scheduled series of immunisations providing protection against preventable infectious diseases across the life course. Vaccination is the single most cost-effective medical intervention in history — responsible for eradicating smallpox, eliminating polio from most of the world, reducing measles deaths by 99%, and preventing an estimated 4-5 million deaths annually worldwide (WHO Global Vaccine Action Plan).

Modern adult vaccination programmes are more complex than childhood schedules, requiring consideration of: (1) age-specific vulnerability — older adults have diminishing immune response requiring adjuvanted or higher-dose formulations; (2) occupational exposure — healthcare workers, laboratory staff, and frequent travellers require targeted immunisations; (3) underlying medical conditions — immunocompromised individuals cannot receive live vaccines but require additional doses of inactivated vaccines; (4) travel destinations — regions endemic for yellow fever, typhoid, Japanese encephalitis, meningococcal disease, and other infections require destination-specific immunisation.

Vaccines work through priming the adaptive immune system — particularly B-lymphocytes producing immunological memory — to recognise and eliminate specific pathogens rapidly before they cause disease. Modern vaccine platforms include inactivated virus (influenza, hepatitis A, IPV), live attenuated virus (MMR, varicella, yellow fever), protein subunit (hepatitis B, HPV, meningococcal B), toxoid (tetanus, diphtheria), conjugate polysaccharide (pneumococcal PCV13/PCV15/PCV20, meningococcal ACWY), mRNA (COVID-19 — mRNA-1273, BNT162b2), and recombinant adjuvanted subunit (Shingrix — superior efficacy via AS01B adjuvant system).

A comprehensive adult vaccination programme provides protection against:

Respiratory Infections: - Influenza (flu): Annual vaccination; 40-60% effective in matched seasons; prevents 3.5 million illnesses, 90,000 hospitalisations annually in the US. High-dose (Fluzone HD) or adjuvanted (FLUAD) formulations for adults 65+. - COVID-19: mRNA vaccines >90% effective vs original strain; updated bivalent/monovalent boosters for emerging variants - Pneumococcal disease: PCV15 or PCV20 for adults 65+ or with chronic conditions; prevents pneumonia, bacteraemia, and meningitis; 50-80% effective against invasive disease - Pertussis (whooping cough): Tdap booster; essential for grandparents and carers of newborns (cocoon strategy)

Vaccine-Preventable Liver Disease: - Hepatitis A: 2-dose series (HAV); essential for travellers to endemic regions, MSM, persons with liver disease - Hepatitis B: 3-dose series or 2-dose (Heplisav-B for adults); near-universal protection; prevents hepatitis B-related cirrhosis and hepatocellular carcinoma

Neurological: - Meningococcal disease: MenACWY for young adults at university; MenB (Bexsero, Trumenba) for high-risk groups; prevents bacterial meningitis and septicaemia - Japanese encephalitis: For travellers to rural Asia; Ixiaro vaccine

Herpesvirus: - Varicella (chickenpox): 2 doses for seronegative adults; prevents primary VZV infection - Herpes zoster (shingles): Shingrix (RZV): 2 doses; 90%+ effective at preventing shingles and postherpetic neuralgia in adults 50+; SUPERIOR to older Zostavax live vaccine

Travel Vaccines: - Yellow fever (live vaccine; required certificate for entry to endemic countries) - Typhoid (Vi polysaccharide injection or Ty21a oral) - Rabies pre-exposure prophylaxis (3-dose series for travellers, vets, wildlife workers) - Cholera (Dukoral oral; for travellers to endemic areas) - Tick-borne encephalitis (TBE); FSME-Immun or Ticovac for travellers to endemic Europe/Asia

Vaccination eligibility is determined by age, health status, occupation, and travel plans.

All Adults: - Annual influenza vaccine - Tdap booster every 10 years (tetanus, diphtheria, acellular pertussis) - Updated COVID-19 booster per national guidance - Hepatitis B: catch-up for those not vaccinated in childhood; all adults to age 59 (ACIP 2022); shared decision-making ages 60+

Adults 50+ (Shingles): - Shingrix (RZV): 2-dose series, 2-6 months apart; high priority — shingles affects 1 in 3 Americans in their lifetime; postherpetic neuralgia can be severely debilitating

Adults 65+ (Pneumococcal): - PCV15 followed by PPSV23 (1 year later) or PCV20 alone - High-dose or adjuvanted influenza formulation

Immunocompromised (additional vaccines; avoid live vaccines): - HIV patients (CD4>200): extra doses of inactivated vaccines; avoid live vaccines (MMR, yellow fever, varicella) if severely immunocompromised - Asplenic/hyposplenic patients: MenACWY, MenB, pneumococcal, Hib — enhanced risk of encapsulated bacterial infection - Post solid organ transplant: all inactivated vaccines; live vaccines contraindicated

Healthcare Workers: - Annual influenza (often mandatory), hepatitis B (serology check post-vaccination), MMR (2 doses documented), varicella (2 doses or serology), COVID-19

Travel: - Depends entirely on destination, itinerary, activities, and duration; travel medicine consultation recommended ≥4-6 weeks before departure for full course completion

Modern vaccination programmes use diverse vaccine platforms optimised for immunogenicity and safety.

Vaccine Platforms: - Live attenuated viral vaccines: MMR, varicella, yellow fever, oral typhoid (Ty21a), oral rotavirus; produce strong, durable immunity (often single dose); contraindicated in pregnancy and immunocompromised individuals - Inactivated vaccines: Influenza (TIV/QIV), hepatitis A, inactivated polio (IPV), rabies, Japanese encephalitis; safe in pregnancy and immunocompromised; typically require booster doses - Subunit/protein vaccines: Hepatitis B (recombinant HBsAg), HPV (VLP), pertussis component in Tdap, meningococcal serogroup B outer membrane vesicle (Bexsero); targeted immune response; no live pathogen; excellent safety profile - Conjugate polysaccharide vaccines: Pneumococcal (PCV13/PCV15/PCV20), Hib, meningococcal ACWY; enhanced T-cell-dependent response vs polysaccharide alone; effective in infants and older adults - mRNA vaccines: BNT162b2 (Pfizer/BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax) for COVID-19; rapid production platform; annual strain updates possible; novel platform with excellent safety data in billions of doses - Recombinant adjuvanted subunit: Shingrix (recombinant VZV glycoprotein E + AS01B adjuvant); 90%+ efficacy due to powerful adjuvant system even in older adults with declining immune function

Delivery Routes: - Intramuscular (IM): Vastus lateralis (thigh) or deltoid (arm); most common; hepatitis A/B, influenza, COVID-19, Shingrix - Subcutaneous (SC): Live viral vaccines (MMR, varicella) — less vascular tissue reduces systemic exposure - Intranasal (IN): LAIV (live attenuated influenza vaccine — FluMist): spray; produces mucosal IgA; preferred in children 2-8 years - Oral: Ty21a (oral typhoid), Dukoral (oral cholera); induces mucosal intestinal immunity appropriate for GI pathogens

Vaccination is among the most impactful medical interventions across all of medicine:

Individual Protection: - Shingrix: 91% effective at preventing herpes zoster (shingles) in adults 50-69; 89% in adults 70+; significant reduction in postherpetic neuralgia — the most debilitating complication - Pneumococcal vaccines: 50-80% effective against invasive pneumococcal disease; hospitalisation-level protection particularly important in adults 65+ - Influenza vaccine: prevents 3.5 million illnesses and 90,000+ hospitalisations annually in the US - HPV vaccination: reduces high-grade cervical lesions by >90% in vaccinated populations; Scotland achieved near-zero cervical cancer rates in HPV-vaccinated birth cohorts

Community (Herd) Immunity: - High vaccination coverage protects unvaccinated individuals (infants too young, immunocompromised) through herd immunity thresholds: >95% for measles, >85% for COVID-19, >80% for influenza - COVID-19 vaccination: significantly reduced hospitalisation and mortality even against evolving variants

Economic Impact: - Every $1 invested in childhood immunisation returns $44 in reduced health costs and social value (JAMA 2020) - Influenza vaccination in working adults reduces absenteeism and employer healthcare costs by $50-100/person/year

Vaccines are among the safest medical interventions but do carry known side effects:

Common (Expected) Side Effects: - Injection site soreness, redness, swelling: 50-85% of recipients; lasts 1-3 days; apply cool compress - Low-grade fever (37.5-38.5°C): 10-30% of recipients after most vaccines; manage with paracetamol - Fatigue, headache, myalgia: particularly after COVID-19 mRNA vaccines and Shingrix; usually 24-48 hours - Arm soreness: particularly after Shingrix — severe in 10-15% but expected and temporary

Uncommon Side Effects: - Febrile seizure: in children with live MMR vaccine (1-2 per 1,000 doses); self-limiting; no long-term sequelae - Intussusception: with older rotavirus vaccine (Rotashield — withdrawn); not seen with current Rotarix or RotaTeq at significant rates

Rare and Serious: - Myocarditis/pericarditis: with mRNA COVID-19 vaccines, primarily in young males post-second dose (estimated 2-7 per 100,000 in males 12-29); typically mild, self-limiting; significantly lower incidence than COVID-19-induced myocarditis - Guillain-Barré syndrome (GBS): rare association with some influenza vaccines; background rate ~1-2 per million doses; compare to COVID-19 risk of GBS - Anaphylaxis: 1.3 per million doses across all vaccines; managed with epinephrine; 15-30 minute post-vaccination observation

Contraindications: - Live vaccines contraindicated in pregnancy (MMR, varicella, yellow fever) and immunocompromised individuals - Allergy to specific vaccine components: gelatin allergy (MMR, varicella, yellow fever), egg allergy (influenza — egg-free alternatives available)

Vaccination programmes require systematic follow-up to maintain protective immunity and adapt to evolving pathogens.

Immediate Post-Vaccination: - 15-30 minutes observation for anaphylaxis at vaccination site - Instructions for managing common local and systemic reactions - Documentation in personal vaccination record (yellow card/digital) - Report unexpected adverse events: UK — Yellow Card scheme; US — VAERS

Schedule Tracking: - Personal vaccination record or digital health app (NHS App, SmartVax, or Immunization Manager) - GP vaccination record — most GP systems automatically track and flag overdue vaccines - Travel health clinic records for travel-specific immunisations

Serology Testing (for Verification): - Hepatitis B surface antibody (anti-HBs) 1-2 months after completing hepatitis B series: confirms protective immunity (>10 mIU/mL) - Varicella IgG for healthcare workers: post-vaccination serology to confirm seroconversion - Rabies post-vaccination serology: for ongoing monitoring of pre-exposure prophylaxis (titre >0.5 IU/mL)

Booster Schedule: - Influenza: annually (each year's formulation updated for circulating strains) - COVID-19: as per evolving national guidance based on variant surveillance - Tdap: every 10 years; Td booster with wound (if >5 years since last dose and wound is dirty) - Shingrix: 2 doses; no boosters currently recommended (long-term follow-up data >10 years showing sustained efficacy)

Vaccination costs vary widely by country and funding mechanism.

India: Single influenza vaccine: INR 500-1,200 ($6-14). Hepatitis B series (3 doses): INR 800-3,000 total ($10-36). Pneumococcal (PCV13): INR 2,000-5,000 ($24-60). HPV (Gardasil 9, 2-3 doses): INR 3,000-12,000 per dose — high cost limits access; Government of India has initiated national HPV vaccination programme for girls aged 9-14. Shingrix (imported): INR 8,000-15,000 per dose. Travel vaccines (hepatitis A, typhoid, yellow fever): INR 1,500-5,000 per dose. Private clinics, hospital vaccine centres, and pharmacies provide adult vaccination; some vaccines available at government primary health centres at no/low cost.

United States: ACA mandates coverage of ACIP-recommended vaccines with no cost-sharing for insured patients — effectively free. Uninsured/underinsured: influenza $25-50, hepatitis B series $50-100, Shingrix $160-200 per dose ($320-400 series), Pneumococcal PCV20 $200-280, HPV 2-dose series $300-500. Vaccines for Children (VFC) programme: free for uninsured, Medicaid-enrolled, and underserved children.

UK (NHS): All national schedule vaccines free on the NHS. Travel vaccines: some free (hepatitis A, typhoid — for UK residents travelling to at-risk areas); others private (hepatitis B £20-100/dose, yellow fever £50-65, rabies £40-70/dose).

When vaccination is contraindicated or was not administered before exposure, post-exposure options exist:

Passive Immunisation (Post-Exposure): - IVIG (intravenous immunoglobulin): Non-specific antibody concentrate; used for hepatitis A, varicella, measles, and rabies post-exposure in unvaccinated individuals - Specific HRIG (human rabies immunoglobulin): Given at wound site after rabies exposure alongside active post-exposure rabies vaccine series; provides immediate protection while vaccine generates active immunity - Varicella-zoster immunoglobulin (VZIG): For immunocompromised patients post-exposure to VZV; administered within 96 hours - HBsAg immunoglobulin (HBIG): After needlestick or sexual exposure to hepatitis B; combined with hepatitis B vaccination

Chemoprophylaxis: - Malaria: Chemoprophylaxis (atovaquone/proguanil, mefloquine, doxycycline) replaces vaccine where no effective vaccine available - Antibiotic prophylaxis: Pre/peri-operative; specific organism-targeted (e.g., penicillin prophylaxis for asplenic patients against pneumococcal and meningococcal sepsis)

Antiviral Prophylaxis: - Oseltamivir (Tamiflu): post-exposure influenza prophylaxis within 48 hours; for high-risk contacts unable to receive influenza vaccine - Aciclovir: valaciclovir for VZV post-exposure in immunocompromised patients where VZIG not available

Note: Post-exposure measures are inferior to pre-exposure vaccination; they should be seen as emergency fallbacks, not planned alternatives to immunisation programmes.